Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2‐Positive Breast Cancer
M Gaibar, L Beltrán, A Romero-Lorca… - Journal of …, 2020 - Wiley Online Library
In one of every four or five cases of breast cancer, the human epidermal growth factor
receptor‐2 (HER2) gene is overexpressed. These carcinomas are known as HER2‐positive …
receptor‐2 (HER2) gene is overexpressed. These carcinomas are known as HER2‐positive …
Crosstalk between HER2 and PD-1/PD-L1 in breast cancer: from clinical applications to mathematical models
Breast cancer is one of the major causes of mortality in women worldwide. The most
aggressive breast cancer subtypes are human epidermal growth factor receptor-positive …
aggressive breast cancer subtypes are human epidermal growth factor receptor-positive …
Precision medicine review: rare driver mutations and their biophysical classification
How can biophysical principles help precision medicine identify rare driver mutations? A
major tenet of pragmatic approaches to precision oncology and pharmacology is that driver …
major tenet of pragmatic approaches to precision oncology and pharmacology is that driver …
Quantum DFT analysis and molecular docking investigation of various potential breast cancer drugs
MA Ayub, AR Tyagi, SK Srivastava… - Journal of Materials …, 2025 - pubs.rsc.org
Breast cancer is among the deadliest cancers worldwide, highlighting the urgent need for
effective treatments. This study employs density functional theory (DFT) and molecular …
effective treatments. This study employs density functional theory (DFT) and molecular …
[HTML][HTML] Depicting biomarkers for HER2-inhibitor resistance: Implication for therapy in HER2-positive breast cancer
Simple Summary The development of HER2-inhibitors for the treatment of HER2-positive
breast cancer represented a breakthrough in targeted tumor therapy. However, as for other …
breast cancer represented a breakthrough in targeted tumor therapy. However, as for other …
Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma
Recent studies have demonstrated that HER2 and MET receptor tyrosine kinases are co-
overexpressed in a subset esophageal adenocarcinoma (EAC). We therefore studied the …
overexpressed in a subset esophageal adenocarcinoma (EAC). We therefore studied the …
Computational investigation of phytochemicals identified from medicinal plant extracts against tuberculosis
Tuberculosis (TB) is still one of the world's most challenging infectious diseases and the
emergence of drug-resistant Mycobacterium tuberculosis poses a significant threat to the …
emergence of drug-resistant Mycobacterium tuberculosis poses a significant threat to the …
6-aminomethylpinostrobin Derivatives as Anti-breast Cancer: In Silico Insight
H Poerwono, MI Sulistyowati… - Egyptian Journal of …, 2024 - journals.ekb.eg
Pinostrobin, a flavanone isolated from various medicinal plants, is known to have various
potential pharmacological activities, one of which is anti-breast cancer. Derivatization of …
potential pharmacological activities, one of which is anti-breast cancer. Derivatization of …
Network biology of lapatinib resistance in different types of HER2-positive breast cancers informs the prioritization of the combination anticancer treatments as anti …
Background: With widespread therapeutic advancement, targeted anticancer therapeutics
are taking over traditional treatment protocols. Nevertheless, the resistance to targeted …
are taking over traditional treatment protocols. Nevertheless, the resistance to targeted …
Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers
RC Doebele - US Patent 11,426,409, 2022 - Google Patents
2020-12-30 Assigned to THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY
CORPORATE reassignment THE REGENTS OF THE UNIVERSITY OF COLORADO, A …
CORPORATE reassignment THE REGENTS OF THE UNIVERSITY OF COLORADO, A …